Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

RSS icon
Cardiovalve heart valve transfemoral TMVR TTVR

Cardiologists first in world to use new heart valve for TMVR, TTVR on same patient

Identical Cardiovalve systems were used to perform the procedures 18 months apart on a high-risk heart patient. 

healthcare value value-based care money dollar

Cardiology Funding Roundup: Cardurion, Kestra, TRiCares all secure key investments

Businesses in the cardiovascular health space have been busy in recent weeks, announcing one big financing round after another. 

Surgeons Operating On Patient

Mechanical valves linked to superior long-term survival after tricuspid valve replacement

Each valve type has its own benefits, researchers noted, but mechanical valves are associated with multiple long-term benefits compared to tissue/bioprosthetic valves. 

M&A mergers and acquisitions business deal

Edwards Lifesciences sells critical care business to BD for $4.2B—remains ‘laser focused’ on structural heart disease

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value. 

Newsweek ranked the 50 best heart hospitals in the world

New York Valves, CRF’s newest cardiology conference, makes heart team collaborations a priority

New York Valves: The Structural Heart Summit replaces the Transcatheter Valve Therapy conference CRF hosted for many years. The three-day event will include 12 late-breaking clinical trials focused on TAVR and new treatments for the mitral and tricuspid valves. 

cardiologist viewing heart data

Cardiologists examine how residual TR after transcatheter tricuspid valve repair impacts survival

Researchers tracked data from more than 600 patients, noting that heart teams may want to reconsider how they classify residual TR after treatment. 

Thumbnail

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries

STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients. 

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Displaying 17 - 24 of 55

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.